4 weeks Krystal Biotech Stock Surges 21.9% in 3 Months: More Room to Grow? Zacks
KRYS has gained 21.9% in the past three months on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.
KRYS has gained 21.9% in the past three months on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.